All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
During the European School of Haematology (ESH) 3rd How to Diagnose and Treat Multiple Myeloma conference, the Multiple Myeloma Hub spoke to Sonja Zweegman, Amsterdam UMC, Amsterdam, NL. We asked, Which 3 things should you consider when treating frail patients?
3 things you should consider when treating frail patients
In this video, Zweegman outlines the levels of frailty in patients over 70, and how therapies such as dexamethasone and lenalidomide can be adapted for intermediate–fit and frail patients. She highlights a recent trial that found patients defined as frail based on their age had superior progression-free survival than those defined as frail because of comorbidities.
HOVON 143: ixazomib, daratumumab & low-dose dexamethasone for unfit & frail patients with NDMM
Sonja Zweegman, Amsterdam UMC – VU University, Amsterdam, NL, discusses the HOVON 143 study: ixazomib, daratumumab & low-dose dexamethasone for unfit &...
IMW 2019 | Management of elderly patients with multiple myeloma
How to manage elderly patients with multiple myeloma, based on an educational presentation at IMW 2019.
Subscribe to get the best content related to multiple myeloma delivered to your inbox